Jupiter Topco LLC bought a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Free Report) during the second quarter, HoldingsChannel reports. The institutional investor bought 1,375,844 shares of the company’s stock, valued at approximately $130,968,000.
Several other institutional investors and hedge funds have also recently modified their holdings of ORKA. J. Goldman & Co LP purchased a new stake in shares of Oruka Therapeutics in the second quarter valued at approximately $1,176,000. ADAR1 Capital Management LLC purchased a new position in Oruka Therapeutics during the 2nd quarter worth $1,983,000. Parkman Healthcare Partners LLC purchased a new position in Oruka Therapeutics during the 2nd quarter worth $10,772,000. Legal & General Group Plc bought a new stake in Oruka Therapeutics during the 2nd quarter valued at $2,874,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Oruka Therapeutics during the 2nd quarter valued at $6,512,000. Institutional investors own 56.44% of the company’s stock.
Oruka Therapeutics Trading Down 2.3%
Shares of NASDAQ ORKA opened at $99.44 on Thursday. Oruka Therapeutics, Inc. has a 12-month low of $14.61 and a 12-month high of $115.51. The stock’s fifty day simple moving average is $93.74 and its two-hundred day simple moving average is $66.89. The stock has a market capitalization of $6.58 billion, a PE ratio of -48.99 and a beta of -0.34.
Insider Buying and Selling
In other Oruka Therapeutics news, CEO Lawrence Otto Klein sold 1,729 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $69.69, for a total value of $120,494.01. Following the completion of the transaction, the chief executive officer directly owned 925,580 shares in the company, valued at approximately $64,503,670.20. The trade was a 0.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Joana Goncalves sold 7,947 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $69.28, for a total transaction of $550,568.16. Following the sale, the insider directly owned 32,718 shares of the company’s stock, valued at approximately $2,266,703.04. The trade was a 19.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 83,116 shares of company stock worth $6,636,533 over the last ninety days. 23.49% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
ORKA has been the topic of a number of recent research reports. Wedbush reissued an “outperform” rating and set a $165.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Guggenheim restated a “buy” rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 11th. UBS Group upped their price objective on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Finally, Piper Sandler reissued an “overweight” rating and set a $180.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $134.30.
Read Our Latest Research Report on Oruka Therapeutics
About Oruka Therapeutics
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Featured Stories
- Five stocks we like better than Oruka Therapeutics
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding ORKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oruka Therapeutics, Inc. (NASDAQ:ORKA – Free Report).
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
